Company intelligence / Profile preview

Atara Biotherapeutics

California & Colorado, United Statesqtac.edu.au ↗

Ownership: Private
Employees: ~80
Development stage: Other

Overview

Atara is the first company to receive approval for an allogeneic T-cell immunotherapy. Its lead product, tabelecleucel (Ebvallo), is approved in Europe for EBV+ PTLD but was rejected by the FDA due to manufacturing concerns. The company has a robust pipeline targeting cancer and autoimmune diseases but recently faced regulatory setbacks and workforce reductions[1][3][7].

Therapeutic areas: ImmunologyNeurologyOncology
Modalities: Allogeneic T-cell therapyChimeric antigen receptor T-cell therapy (CAR-T)Cell therapy
Industry: Biotech

Partnerships

Pierre Fabre Laboratories (commercialization partner for Ebvallo outside Europe)HealthCare Royalty financing agreementacademic partnerships with Memorial Sloan Kettering Cancer Center and QIMR Berghofer[2][3]

Beyond the preview

Go deeper on Atara Biotherapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Atara Biotherapeutics.

Explore the full profile